These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26927097)

  • 1. Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease.
    Shteyer E; Villenchik R; Mahamid M; Nator N; Safadi R
    Int J Mol Sci; 2016 Feb; 17(3):312. PubMed ID: 26927097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?
    Baratta F; Pastori D; Ferro D; Carluccio G; Tozzi G; Angelico F; Violi F; Del Ben M
    World J Gastroenterol; 2019 Aug; 25(30):4172-4180. PubMed ID: 31435171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients.
    Selvakumar PK; Kabbany MN; Lopez R; Tozzi G; Alisi A; Alkhouri N; Nobili V
    Dig Liver Dis; 2016 Aug; 48(8):909-13. PubMed ID: 27198736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease.
    Tovoli F; Napoli L; Negrini G; D'Addato S; Tozzi G; D'Amico J; Piscaglia F; Bolondi L
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28587063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease.
    Ferri F; Mischitelli M; Tozzi G; Messina E; Mignini I; Mazzuca S; Pellone M; Parisse S; Marrapodi R; Visentini M; Baratta F; Del Ben M; Pastori D; Perciballi R; Attilia ML; Carbone M; De Santis A; Violi F; Angelico F; Ginanni Corradini S
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00116. PubMed ID: 32463622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease.
    Polimeni L; Pastori D; Baratta F; Tozzi G; Novo M; Vicinanza R; Troisi G; Pannitteri G; Ceci F; Scardella L; Violi F; Angelico F; Del Ben M
    Intern Emerg Med; 2017 Dec; 12(8):1159-1165. PubMed ID: 28900817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?
    Baratta F; Pastori D; Polimeni L; Tozzi G; Violi F; Angelico F; Del Ben M
    Int J Mol Sci; 2015 Nov; 16(12):28014-21. PubMed ID: 26602919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.
    Angelico F; Corradini SG; Pastori D; Fargion S; Fracanzani AL; Angelico M; Bolondi L; Tozzi G; Pujatti PL; Labbadia G; Corazza GR; Averna M; Perticone F; Croce G; Persico M; Bucci T; Baratta F; Polimeni L; Del Ben M; Violi F;
    Atherosclerosis; 2017 Jul; 262():179-184. PubMed ID: 28396038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease.
    Baratta F; Pastori D; Del Ben M; Polimeni L; Labbadia G; Di Santo S; Piemonte F; Tozzi G; Violi F; Angelico F
    EBioMedicine; 2015 Jul; 2(7):750-4. PubMed ID: 26288848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis?
    Gravito-Soares M; Gravito-Soares E; Gomes D; Tome L
    Ann Hepatol; 2019; 18(1):78-88. PubMed ID: 31113613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease.
    Baratta F; Pastori D; Tozzi G; D'Erasmo L; Di Costanzo A; Arca M; Ettorre E; Ginanni Corradini S; Violi F; Angelico F; Del Ben M
    Liver Int; 2019 Dec; 39(12):2301-2308. PubMed ID: 31392821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD.
    Carter A; Brackley SM; Gao J; Mann JP
    J Hepatol; 2019 Jan; 70(1):142-150. PubMed ID: 30315827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal acid lipase deficiency allograft recurrence and liver failure- clinical outcomes of 18 liver transplantation patients.
    Bernstein DL; Lobritto S; Iuga A; Remotti H; Schiano T; Fiel MI; Balwani M
    Mol Genet Metab; 2018 May; 124(1):11-19. PubMed ID: 29655841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures.
    Gomaraschi M; Fracanzani AL; Dongiovanni P; Pavanello C; Giorgio E; Da Dalt L; Norata GD; Calabresi L; Consonni D; Lombardi R; Branchi A; Fargion S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Dec; 1864(12):158523. PubMed ID: 31505261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal Acid Lipase Deficiency Unmasked in Two Children With Nonalcoholic Fatty Liver Disease.
    Himes RW; Barlow SE; Bove K; Quintanilla NM; Sheridan R; Kohli R
    Pediatrics; 2016 Oct; 138(4):. PubMed ID: 27624512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clinical characterization of a series of patients with childhood-onset lysosomal acid lipase deficiency. Retrospective investigations, follow-up and detection of two novel LIPA pathogenic variants.
    Pisciotta L; Tozzi G; Travaglini L; Taurisano R; Lucchi T; Indolfi G; Papadia F; Di Rocco M; D'Antiga L; Crock P; Vora K; Nightingale S; Michelakakis H; Garoufi A; Lykopoulou L; Bertolini S; Calandra S
    Atherosclerosis; 2017 Oct; 265():124-132. PubMed ID: 28881270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic changes and propensity for inflammation, fibrosis, and cancer in livers of mice lacking lysosomal acid lipase.
    Bradić I; Liesinger L; Kuentzel KB; Vujić N; Trauner M; Birner-Gruenberger R; Kratky D
    J Lipid Res; 2023 Sep; 64(9):100427. PubMed ID: 37595802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy.
    Reynolds TM; Mewies C; Hamilton J; Wierzbicki AS;
    J Clin Pathol; 2018 Jul; 71(7):608-613. PubMed ID: 29358478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.
    Maciejko JJ
    Am J Cardiovasc Drugs; 2017 Jun; 17(3):217-231. PubMed ID: 28197978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review.
    Bashir A; Tiwari P; Duseja A
    Ther Adv Rare Dis; 2021; 2():26330040211026928. PubMed ID: 37181111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.